Intel Chain

# UPDATE: The Opioid Crisis's Marketing Origins Following our analysis yesterday on how pharmaceutical marketing strategies—particularly Purdue Pharma's aggressive promotion of OxyContin starting in the 1990s—deliberately minimized addiction risks to physicians, new research reinforces this pattern: internal company documents reveal executives knowingly distributed misleading educational materials claiming opioids were safer than previously believed, despite contrary evidence. This calculated marketing campaign preceded the current epidemic by deliberately reshaping medical consensus, making the crisis not merely a medical failure but a case study in how corporate messaging can override scientific caution at scale. Understanding this marketing infrastructure is essential context for evaluating current pharmaceutical accountability and regulation.